ARVN's logo.
Ticker Symbol: ARVN

Arvinas Inc

$80.00 - 04-12-2024 4 p.m. ET

Exchange: NASDAQ Country: US Currency: USD Asset Type: Common Stock CIK:0001655759

Company Profile

arvinas is a pharmaceutical company focused on developing new small molecules ‒ known as protacs (proteolysis targeting chimeras) ‒ aimed at degrading disease-causing cellular proteins via proteolysis. based on innovative research conducted at yale university by dr. craig crews, founder and chief scientific advisor, the company is translating natural protein degradation approaches into novel drugs for the treatment of cancer and other diseases. the proprietary protac-based drug paradigm induces protein degradation, rather than protein inhibition, using the ubiquitin proteasome system and offers the advantage of potentially targeting “undruggable” as well as “druggable” elements of the proteome. this greatly expands the ability to create drugs for many new, previously unapproachable targets. for more information, visit www.arvinas.com.

Sector: Manufacturing
Industry: Medicinal and Botanical Manufacturing
Standard Industrial Classification Code (SIC code): 2834
Address: 5 Science Park 395 Winchester Ave
Website: arvinas.com
CEO: John G. Houston
Tags:
  • Health Technology
  • Biotechnology
  • Manufacturing
  • Medicinal and Botanical Manufacturing

Pricing

Last Updated: October 20, 2023 03:00 PM EST
Previous Close: $14.83
Change: -$0.45 ( -2.94%)
Days Range: $14.70 - $15.29
Beta: 1.60
52wk. High: $57.96
52wk. Low: $15.14
Ytd. Change -59.60%
50 Day Moving Average: $21.67
200 Day Moving Average: $24.36
Shares Outstanding: 53485023

Valuation

Market Cap: 79.3B
PE Ratio: -2.66
EPS (TTM): -5.58

Dividends

Dividend Per Share (TTM): -
Dividend Yield (TTM): 0.00%
Ex-Dividend Date: N/A